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Abstract
Background: The role of TGF-β1 in lymph node metastasis and lymphangiogenesis, one of the most important
steps of gastric cancer dissemination, is largely unknown. The goal of this study was to investigate the role of TGF-
β1 signaling and its molecular mechanisms involved in lymphangiogenesis of gastric cancer.
Methods: Two gastric cell line models, MKN45 and KATOIII, were selected for this study. The protein expression of
TGF-β1 pathway molecules and VEGF-C were examined with western blot, or ELISA according to TGF-β1 treatment.
To explore whether Smad3 binds to the specific DNA sequences in the VEGFC promoter, we performed an
electrophoretic mobility shift assay. Lymphatic tube forming assay and gastric cancer xenograft mouse models were
also used to elucidate the effect of TGF-β1 on lymphangiogenesis.
Results: TGF-β1 induced the activation of Smad2/3 and Smad pathway-modulated VEGF-C expression in gastric
cancer cell line models. Phosphorylated and activated Smad3 in the nucleus bound to the promoter of VEGFC in
KATO III cells. Of note, in MKN45 cells, the Smad-independent AKT pathway was also activated in response to TGF-
β1 and induced VEGF-C expression. Inhibition of TGF-β1 signaling down-regulated the expression of VEGF-C. We
also confirmed, through tube forming assay and tumor xenograft mouse model, that TGF-β1 increased lymphatic
formation, while TGF-β1 inhibition blocked lymphangiogenesis.
Conclusion: Smad-dependent and -independent TGF-β1 pathways induce VEGF-C, which make lymphangiogenesis
around tumor. These findings suggest that TGF-β might be a potential therapeutic target for preventing gastric
cancer progression and dissemination.
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Background
Tumor-induced lymphangiogenesis has been studied to
have an association with lymph node metastasis and
poor prognosis of cancer patients [1–7]. It is regard as
not a simple route of cancer to regional lymph node, but
behaves an active role for metastasis. The most well
studied mechanism of lymphangiogenesis is VEGF-C/D
and VEGFR3 interacting axis between cancer cells and
lymphatic endothelial cells [8, 9].
For gastric cancer, lymph node metastasis and lym-
phangiogenesis is one most significant prognostic factor
determining the clinical outcomes after curative intent
treatment. Recent multicenter transcriptome studies [10]
and The Cancer Genome Atlas study [11] showed that
TGF-β may play an important role in gastric cancer biol-
ogy and progression. Until now, TGF-β can lead bad
prognosis of cancer patients by promoting epithelial-
mesenchymal transition (EMT), leading to invasion and
metastasis [12, 13]. However, the effect of TGF-β for
lymphangigoenesis, which is the one of the most import-
ant steps during metastasis of cancer, has been largely
unknown.
Here, we investigated the role and molecular signaling
mechanism of TGF-β1 for lymphangiogenesis in gastric
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cancer. We elucidated that TGF-β1 promotes VEGF-C
production through Smad-dependent way or Smad-inde-
pendent one, according to each cell type, which leads to
lymphangiogenesis in gastric cancer in vitro and in vivo
experimental model. Our study provide insight for un-
derstanding TGF- β cancer biology and a new target for
cancer treatment.
Methods
Cell culture
The human gastric cancer cell lines AGS, MKN28,
MKN45, NCI-N87, SK4, KATOIII, Hs746T, and YCCs
were maintained in RPMI 1640 medium (Hyclone, South
Logan, Utah) containing 10% fetal bovine serum, 100 U/
ml of penicillin sodium, and 100 μg/ml of streptomycin
sulfate at 37 °C in a humidified incubator containing 5%
CO2. Cultured human lymphatic endothelial cells
(HLECs) were purchased from Promo Cell (Promo Cell,
Heidelberg, Germany). This cell line was maintained in
complete medium (Endothelial cell growth medium 1;
Promo Cell, Heidelberg, Germany) on gelatin-coated
dishes. HLECs were used between passages 5 and 8.
Human gastric cell lines MKN45 and KATOIII were
obtained in May 2007 from American Type Culture Col-
lection (ATCC, Manassas, VA, USA). AGS, MKN28,
NCI-N87 and Hs746T were purchased in March 2007
from the Korean Cell Line Bank (Seoul, Korea). SK4 cells
were a kind gift in May in 2009 from Dr. Julie Izzo (MD.
Anderson Cancer Center, Texas, USA). YCC-series cell
lines were obtained from in September 2006 the Song-
Dang Institute for Cancer Research, Yonsei University
College of Medicine (Seoul, Korea). The identifies of all
cell lines were validated by short tandem repeat (STR)
DNA fingerprinting using the AmpFISTR identifier kit,
according to the manufacturer’s guidelines (Applied Bio-
systems; 4322288) at the Characterized Cell Line Core Fa-
cility. The STR profiles were compared with known
ATCC fingerprints (ATCC.org) and to the Cell Line Inte-
grated Molecular Authentication (CLIMA) database ver-
sion 0.1.200808 (http://bioinformatics.hsanmartino.it/
clima2/; Nucleic Acids Research 37:D925-D932 PMCID:
PMC2686526). Mycoplasma contamination was checked
by Mycoplasma PCR Detection Kit (Sigma-Aldrich;
MP0035) to ensure that there was no mycoplasma con-
tamination before and after the study.
Western blot analysis
Cells were washed cold PBS and lysed on ice with protein
extraction buffer (Pro-Prep, iNtRON Biotechnology,
Seoul, Korea). Equal amounts of protein were loaded onto
a sodium dodecyl sulfate-polyacrylamide gel (12% poly-
acrylamide) and transferred to polyvinylidene floride
(PVDF) membrane. The membranes were blocked with 5%
nonfat milk in TBS-T and incubated with appropriate
concentrations of primary antibodies anti-TGFβ receptor II
(TβR2), Smad3, P-Erk, P-Akt, Akt, P-Rho, Rho, VEGF-C
(dilution 1:1000; cell signaling Technology, Massachusetts,
USA) and anti-β-actin (dilution 1:1000; Sigma-Aldrich,
USA) antibodies were diluted in TBS-T (TBS/Tween 20:
2% skim milk). The appropriate secondary antibodies were
applied (dilution 1:5000, horseradish peroxidase-conjugated
anti-rabbit and anti-mouse) at room temperature for 1 h.
Labeled bands were detected by enhanced chemilumines-
cence (ECL; ThermoScientific, USA).
Electrophoretic mobility shift assay (EMSA)
The DNA binding activity of Smad3 against the VEGFC
promoter was studied with a 32P-labeled oligonucleotide
encoding the Smad3 transcription factor binding sites
found in the VEGFC promoter region [14–16]. We first
used the Alibaba 2.1 algorithms to search the TRAN
SFAC database to identify potential Smad3-binding sites
to VEGFC promoter. This search revealed the presence of
Smad3 binding sites to VEGFC promoter. Double-stranded
oligonucleotides including the consensus-binding site for
Smad3 sense: GTCGGCCAGC -CACTCGCATTGTGA
CTA, anti-sense: TAGTCACAATGCGAGTGGCTGGCC
GAC and Mutant Smad3 sense: GTCGCGGAGCCACT
CGCTAACTGACTG, anti-sense: CAGTCA -GTTAGC
GAGTGGCTCCGCGAC were 5′ end-labeled with poly-
nucleotide kinase and ɣ-32P-dATP. Details are described in
our previous articles [17].
Tube formation assay
HLECs (1 × 105) were cultured in a 24-well plate coated
with 150 μl of Growth factor-diminished Matrigel in
MV1 medium for cell attachment for 1 h. The MV1
medium was substituted with conditional medium and
continuous cell culture for 24 h. Then, tube length was
calculated after 8 h by checking the total cumulative
tube length in three random microscopic fields with
NIH ImageJ1.44 image analysis software, which is avail-
able at https://imagej.nih.gov/ij/. The original magnifica-
tion used was × 100.
Enzyme-linked immunosorbent assay (ELISA)
Protein contents in culture medium were determined
with Quantikine Immunoassay systems for human
VEGF-C enzyme-linked immunosorbent assay (ELISA)
kit (R&D Systems, Minneapolis, MN, USA). Content of
target protein in culture medium was expressed as the
quantity of protein secreted from 10,000 cells for 24 h.
Human GC (gastric cancer) cell lines xenograft model
The human GC cell lines MKN45 and KATOIII (1.5 ×
106 cells/mouse) were cultured in vitro and then injected
subcutaneously into the upper left flank region of female
BALB/c nude mice. After 10 days, tumor-bearing mice
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were grouped randomly (n = 8/group) and treated daily
oral dosing at 75 mg/kg TGF-β inhibitor (LY2157299).
Tumor size was measured every other day using calipers.
Tumor volume was estimated using the following for-
mula: (LxS2)/2 (where L, longest diameter; S, shortest
diameter) [18]. Female BALB/c nude mice were pur-
chased from the Orient Animal Co. Ltd. (Seongnam,
Gyeonggi-do, Korea). Mice were sacrificed by CO2 as-
phyxiation, and tumors were excised. All animals were
sustained under specific pathogen-free (SPF) conditions.
All experiments received the Animal Experiment Com-
mittee of Yonsei University and the Institutional Review
Board of Severance Hospital, Yonsei University (4–2012-
0427) approval.
Statistical analysis
Values are expressed as means ± S.D. Mann-Whitney
test was used to evaluate the data. For cell tube assay
analysis, One-Way ANOVA was used to assess statistical
significance. Differences were rated to be statistically sig-
nificant at P < 0.05. All analyses were excuted with SPSS
21 software (SPSS, Chicago, IL).
Results
GC cells which show TGF-β1, TβR2 and VEGF-C are
selected as the model cell lines
To select model cell lines suitable for testing the hypoth-
esis, we examined the expression of TGF-β1, TβR2 and
VEGF-C in a panel of gastric cancer cell lines (AGS,
MKN28, MKN45, NCI-N87, SK4, KATOIII, HS746T) by
western blot analysis. TGF-β1 and TGF-β1 receptor II
were expressed in all seven gastric cancer cell lines ex-
amined (Fig. 1a), whereas VEGF-C was expressed only in
MKN45 and KATOIII (Fig. 1b) cell lines. Based on these
results, we selected MKN45 and KATOIII as model cell
lines for improving the role of TGF-β1 signaling on
lymphangiogenesis.
GC cells secrete TGF-β1 and shows paracrine effect
We further investigated additional gastric cancer cell lines
and found that YCC2 and YCC3 only express a significant
amount of TβR2, but not TGF-β1 (Additional file 1: Fig-
ure S1A). We ascertained the existence of TGF-β1 in con-
ditioned media of MKN45 and KATOIII but not in YCC2
(Additional file 1: Figure S1B). We noticed that Smad2
and Smad3, the receptor activated Smads (R-Smads), were
phosphorylated and activated in YCC2 cells when treated
with the conditioned media of MKN45 and KATOIII
(Additional file 1: Figure S1C). Therefore, we confirmed
that our gastric cancer cell-line models (MKN45 and
KATOIII) produce TGF-β1, which can regulate other cells
in paracrine fashion.
GC cells are confirmed to have a normal response to TGF-
β1 and its inhibitor
To confirm the validity of these model cell lines for TGF-
β1 responsiveness, MKN45 and KATOIII cells were treated
with TGF-β1 (10 ng/ml) and were analyzed for target gene
expression. As shown in Additional file 2: Figure S2A, the
mRNA expression of twist1, a well-established target gene
of the TGF-β1 signaling pathway, was significantly induced
by TGF-β1 treatment in both cell lines. In addition, the cor-
responding increase of phosphorylation of Smad3 was evi-
dent in TGF-β1-treated cells (Additional file 2: Figure S2B).
Further, the treatment of TGF-β1 receptor I inhibitor
(LY2157299) abrogated the effect of TGF-β1-induced phos-
phorylation of Smad3, confirming intact and functioning
TGF-β1 signaling in these cell lines (Additional file 2: Fig-
ure S2C).
GC cells transduce TGF-β1 signaling through
translocation of cytosolic P-Smad3 into nucleus
To investigate the effect of TGF-β1 on the expression of
VEGF-C, we treated KATOIII cells with TGF-β1 and/or
TGF-β1 receptor I inhibitor (LY2157299), as indicated.
In KATOIII cells, the expression of phosphorylated form
P-Smad3, not P-Smad2, was down-regulated in response
Fig. 1 TGF-β1, TGF-β1 receptor II, and VEGF-C expression in gastric cancer cells. Among gastric cancer cell lines, MNK45 and KATOIII were
selected as a model for the regulation of TGF-β1 on lymphangiogenesis. These two cell lines expressed TGF-β1, TGF-β receptor II (a), and VEGF-C
(b). TβR2, TGF-β receptor 2
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to LY2157299. Furthermore, it was repressed in dose-
dependent manner (Fig. 2a). To examine whether acti-
vated Smad3 was translocated to nuclear from cytoplasm
in response to TGF-β1, we analyzed the expression level
of both P-Smad3 and total form Smad3 in nucleus and
cytosol according to the treatment of TGF-β1 and
LY2157299. The expression of P-Smad3 in the nucleus
was increased with TGF-β1, while it was decreased with
LY2157299 (Fig. 2b).
Translocated P-Smad3 binds directly to the promoter
region of VEGF-C
To elucidate whether TGF-β1 signaling-induced lymphan-
giogenesis is mediated through increased transcription of
Fig. 2 Smad-dependent pathway of TGF-β1 signaling. a LY2157299 suppressed the expression of phospho-Smad3 in KATOIII. b The change in p-
Smad3 expression in response to TGF-β1 in the cytosol and nucleus. In KATOIII cells, the amount of nucleus p-Smad was increased in response to
TGF-β1, while decreased in response to LY2157299. Lamin and GAPDH were used as a loading controls in the nucleus and cytosol, respectively
Fig. 3 EMSA between Smad3 and VEGFC. a The binding site of Smad3 to the promoter of VEGFC. b KATOIII cells (lane 6 and 8) showed
significantly increased binding activity between Smad3 and the VEGFC promoter region compared to MKN45 cells (lane 5 and 7). NE,
nuclear extract
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VEGF-C, we first investigated the interaction between
transcription regulator Smad3 and the promoter region of
VEGFC. A few Smad3 binding sites have been identified
in the VEGFC promoter region. We carried out an EMSA
with a 32P-labeled oligonucleotide containing Smad3 bind-
ing sites found in the VEGFC promoter (Fig. 3a). Labeled
Smad3 probe-nuclear extract (from the MKN45 and
KATOIII cells) complexes produced two bands. The spe-
cificity of the EMSA result was confirmed by complete in-
hibition of Smad3 DNA binding by excess labeled and
unlabeled Smad3 (lane 1, 4, Fig. 3b). In addition, a similar
amount of mutated Smad3 probe also failed to bind to the
Smad3 transcription complex (lane 2, Fig. 3b).
In KATOIII cells (lane 3, 6, Fig. 3b) Smad3 binding ac-
tivity to the VEGFC promoter regions significantly in-
creased compared to that in MKN45 cells (lane 5, Fig. 3b).
The binding signals were increased with five times more
nuclear extract alone (lane 7 and 8, Fig. 3b). To assure the
binding interaction between Smad3 and the promoter of
VEGFC, a super-shift assay with anti-Smad3 antibody was
performed and showed more potentiated signals (lane 9
and 10, Fig. 3b). Furthermore, that response was potenti-
ated by more concentrated nucleic extract (lane 11 and
12, Fig. 3b). Together, these results demonstrate that
Smad3 can bind to the promoter of the VEGFC gene.
Inhibition of TGF-β1 signaling suppresses
lymphangiogenic VEGF-C expression
Next, we examined whether the inhibition of TGF-β1
signaling in model cell lines suppresses VEGF-C expres-
sion. By western blot analysis of conditioned media of
KATO III and MKN45 cells, we demonstrated that the
protein level of VEGF-C is decreased when treated with
LY2157299 (Fig. 4). Based on these results, we con-
firmed that TGF-β1 signaling promotes VEGF-C expres-
sion in gastric cancer cells.
Fig. 4 The expression of VEGF-C in response to TGF-β1 receptor I inhibitor. TβR1 inhibitor, TGF-β receptor 1 inhibitor
Fig. 5 Smad-independent pathway of TGF-β1 signaling. a Only p-Akt was remarkably increased in response to TGF-β1 in MKN45, not in KATOIII
cells. b Phospho-Akt was increased in response to TGF-β1 but decreased in response to LY2157299
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Some GC cells are capable of transducing TGF-β1
signaling through Smad-independent pathway, especially
AKT pathway
According to the EMSA results, the binding inter-
action between Smad3 and the VEGFC promoter re-
gion is weaker in MKN45 than KATOIII cells. These
findings may suggest the existence of other TGF-β1
signaling pathways for VEGF-C activation in MKN45,
which are different from the Smad-dependent path-
way. Therefore, we examined Smad-independent sig-
naling pathway molecules. Among them, phospho-Akt
(P-Akt) was remarkably induced in response to TGF-
β1 treatment in only MKN45 cells, not KATOIII cells
(Fig. 5a). P-Akt was increased when treated with
TGF-β1, but decreased when treated with its inhibitor
LY2157299 in MKN45 cells (Fig. 5b). Taken together,
TGF-β1 signals may be transduced through Smad-
dependent and Smad-independent pathways according
to specific gastric cancer cell line.
TGF-β1 proliferates lymphatic endothelial cells via VEGF-C
production
Next, we validated the effect of TGF-β1 signaling on lym-
phangiogenesis by conducting a lymphatic endothelial cell
tube formation assay. HLECs were cultured in the condi-
tioned media of MKN45 and KATOIII cells. After 18 h of
culture, we noticed the formation of a tubular structure of
HLECs in MKN45- and KATOIII-conditioned media com-
pared to HLECs alone or in YCC2-conditioned media. The
length of HLECs in MKN45- and KATOIII-conditioned
media was increased compared to HLECs alone or with
YCC2-conditioned media (Additional file 3: Figure S3A).
The tube length was decreased with in response to TGF-β
receptor 1 inhibitor, LY2157299 (Additional file 3: Figure
S3B). Quantitation of the results was confirmed by measur-
ing the length of tube formation of HLECs. The length of
its tube was longer in MKN45- and KATOIII-conditioned
media than in control media (P < 0.01, 0.001 each) (Fig. 6a).
In YCC2-conditioned media, the length of tube was
Fig. 6 The quantitation of tube formation of HLECs. a The length of its tube was longer in MKN45- and KATOIII-conditioned media than
in HLEC alone. b With YCC2-conditioned media, only TGF receptor-expressing cell line showed increased tube length with TGF-β1. c-d
With MKN45 and KATOIII-conditioned media, the tube length was increased for TGF-β1 and deceased with TβR1 inhibitor. TβR1, TGF-β
receptor 1. (*P < 0.05, **P < 0.01, ***P < 0.001, One-Way ANOVA)
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increased with addition of TGF-β1 (P < 0.05) (Fig. 6b). In
MKN45 and KATOIII-conditioned media, the tube length
was increased with TGF-β1 (P < 0.05) and deceased with
TβR1 inhibitor, LY2157299 (P < 0.05 in MKN45, P < 0.01
in KATOIII) (Fig. 6c, d). The expression level of secreted
VEGF-C in YCC2-, MKN45-, and KATOIII-conditioned
media according to the treatment of TGF-β1 and
LY2157299 was also investigated by ELISA analysis. The
level of VEGF-C was increased with TGF-β1 in YCC2-
conditioned media (P < 0.001) (Additional file 4: Figure
S4A). The level of VEGF-C was increased with TGF-β1
(P < 0.01 in MKN45, P < 0.05 in KATOIII), but decreased
with LY2157299 (P < 0.05 in MKN45, P < 0.01 in
KATOIII) (Additional file 4: Figure S4B, C).
TGF-β1 receptor inhibitor suppresses gastric cancer
progression and lymphangiogenesis in mouse xenograft
tumor models
To study the anti-tumor effect of TGF-β1 receptor in-
hibitor in vivo, we developed mouse xenograft tumor
models using MKN45 and KATOIII cell lines.
LY2157299 treatment showed significant suppression of
xenografted tumors (P < 0.01) (Fig. 7a, b). Furthermore,
it decreased tumor volume in dose-dependent manner
(P < 0.01) (Fig. 7c). To confirm the suppressive effect of
tumor lymphangiogenesis by TGF-β1 receptor inhibitor,
we analyzed D2–40 (the marker of small lymphatic ves-
sels) expressions in tumor tissues by immunohistochem-
ical analysis. LY2157299 treated-tumor tissues showed
much lower expressions of D2–40 than control (P <
0.01) (Fig. 7d).
Discussion
Our study shows that TGF-β1 signaling which is acti-
vated in gastric cancer cells can transcriptionally induce
VEGF-C expression, which leads to enhanced tube for-
mation of HLECs in vitro and in vivo. Furthermore, the
affecting signaling pathway of TGF-β1 for VEGF-C regu-
lation can be transduced through Smad-dependent or
Smad-independent manner in according to different
types of gastric cancer cells. The results of this study
were supported with the experiment of HLEC tube for-
mation assay and ELISA of secreted VEGF-C in the con-
ditioned media of gastric cancer cells. In addition,
gastric cancer cell-line mouse xenograft model showed
increased lymphangiogenesis with TGF-β1, while de-
creased lymphangiogenesis with TGF-β1 inhibitor. This
study is the first report to demonstrate the mechanism
of how TGF-β1 affects lymphangiogenesis in gastric
Fig. 7 TGF- β1 promotes tumor growth and lymphangiogenesis in mouse xenograft model. a TGF-β1 inhibitor reduces tumor volume in MNK45
xenograft mouse model. b TGF-β1 inhibitor reduces tumor volume in KATOIII xenograft mouse model. c TGF-β1 inhibitor reduces the volume of
xenograft model in dose-dependent manner. d Lymphovascular density with D2–40 immunohistochemistry. LY2157299 inhibits
lymphangigoenesis in both types of gastric cancer tissue. (*P < 0.05, **P < 0.01, Mann-Whitney test)
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cancer cell models through investigating both Smad-
dependent and Smad-independent pathways.
TGF-β signaling consists of two pathways. One is ca-
nonical Smad-dependent pathway and the other is Smad-
independent one. TGF-β binds to TGF-β receptor II and
I, which phosphorylates Smad2/3. It forms complex with
Smad4 in cytosol, which can move into nucleus. Then, it
plays a role as transcriptionally regulatory factor for target
gene. The Smad-independent pathway includes the phos-
phoinositol-3 kinase (PI3K), mitogen-activated protein
kinase (MAPK), and small guanosine triphosphatase
(GTPase) pathways.
Recent studies in gastric cancer [10, 11], colon can-
cer [19] and hepatocellular carcinoma [20, 21] have
brought great interest in the role of TGF-β on gastric
cancer biology. TGF-β1 has been known to have a
distinct biphasic role in tumor progression. It func-
tions as a tumor suppressor in early stages of cancer,
while a tumor promoter in late stages [12, 13]. This
dual role of TGF-β1 on tumor biology makes it diffi-
cult to understand its mechanism and to apply it
therapeutically to a clinical setting. In addition, the
reciprocal relation between cancer and surrounding
stromal cells, such as lymphocytes, macrophage, fibro-
blast, etc., makes the situation more complex and
complicated [22]. TGF-β1 has many oncogenic effects
like epithelial-mesenchymal transition (EMT), angio-
genesis, evasion of immune surveillance and stem cell
maintenance. However, the role of TGF-β1 on lym-
phangigoenesis is largely unknown, despite the fact
that lymphangiogenesis and lymph node metastasis is
one most significant prognostic factor in many types
of cancers. Recent some studies suggest that TGF-β1
might upregulate VEGF-C expression in renal tubular
cell, implying that TGF-β1 might contribute to tumor
lymphangiogenesis [23].
The data in this study suggest that TGF-β1 signal-
ing can upregulate VEGF-C expression, which leads
to lymphangiogenesis in gastric cancer. The signals of
TGF-β1 to transcriptional induction of VEGF-C can
be mediated via canonical Smad3 in some gastric can-
cer cells, while it can also be conveyed via the non-
canonical Smad-independent Akt pathway. However,
LY2157299 (Galunisertib, Eli Lilly) which is used in
this study as a TβR1 small molecule inhibitor might
be thought to inhibit both Smad-dependent and
Smad-independent pathways, because both pathways
are downstream of the common upstream complex of
TGF-β1 and TβR1 [12]. Combination of galunisertib
with PD-L1 blockade resulted in improved tumor
growth inhibition of hepatocellular carcinoma [21].
Thus, our results support that LY2157299 can be a
new therapeutic agent against gastric cancer progres-
sion and metastasis.
Conclusion
Smad-dependent and -independent TGF-β1 pathways
induce VEGF-C, which make lymphangiogenesis around
tumor. These findings suggest that TGF-β might be a
potential therapeutic target for preventing gastric cancer
progression and dissemination.
Additional files
Additional file 1: Figure S1 Paracrine regulation of TGF-β1. (A-B) YCC2
was selected as a paracrine model of TGF-β1 production. (C) Smads were
detected only in the total cell lysate of YCC2, which was cultured in the
conditioned media of MKN45 and KATOIII cells. (TIF 945 kb)
Additional file 2: Figure S2 Activated TGF-β1 signaling in MKN45 and
KATOIII gastric cancer cells The expression of twist I (A) and p-Smad3 (B)
were enhanced in responding to TGF-β1, but was decreased at TGF-β1
receptor inhibitor (LY2157299) (C). (TIF 931 kb)
Additional file 3: Figure S3 Lymphatic endothelial cell (HLEC) growth
in the conditioned media of gastric cancer cells. The growth of HLEC in
MKN45- and KATOIII-conditioned media was increased compared to
HLECs alone or with YCC2-conditioned media. However, tube formation
was decreased in responding to TGF receptor I inhibitor. All photos were
taken after 8 h of culture. CM, conditioned media; TβR1 inh., TGF-β
receptor 1 inhibitor. (TIF 3336 kb)
Additional file 4: Figure S4 The level of VEGF-C in the conditioned
media of gastric cancer cell lines. (A) YCC 2-conditioned media resulted
in an increased level of VEGF-C with TGF-β1. (B-D) The level of VEGF-C
was increased with TGF-β1, but decreased with TβR1 inhibitor in MKN45-
and KATOIII-conditioned media treatments. TβR1, TGF-β receptor 1. *P <
0.05, **P < 0.01, ***P < 0.001, One-ANOVA test). (TIF 871 kb)
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